Alkermes plc.
Alkermes (ALKS) officer Craig C. Hopkinson filed a Rule 144 notice for potential sales of 9,000 ordinary shares, valued at $422,874.27. The shares include those from an employee stock option exercise, performance share award vesting, and restricted stock unit vesting. Alkermes had 167,763,272 ordinary shares outstanding as of 09/01/2026.
Alkermes' investigational narcolepsy drug alixorexton showed statistically significant improvements in wakefulness and cataplexy in a phase 2 study. The treatment was well-tolerated and improved patient-reported outcomes. The company has initiated a phase 3 program based on these results, according to the company.
Alkermes (ALKS) shares rose 1.7% since its last earnings report, beating estimates with Q2 2026 revenue of $496M (up 27% YoY) and break-even earnings. Key products like Vivitrol and Lybalvi showed mixed sales growth. The company reiterated its 2026 guidance, expecting $1.73B-$1.84B in total revenue. Analysts have revised estimates downward, and the stock has a Zacks Rank #3 (Hold).
Over the past 7 days, alphai's AI scored 1 news story mentioning ALKS (Alkermes plc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent ALKS coverage spans technology, financial news and earnings.
In the last 30 days, ALKS insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($893K). The most active reporter was Nichols Christian Todd, SVP, Chief Commercial Officer, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The insider sale could modestly increase share supply and put slight downward pressure on the stock.
Positive Phase 2 results may boost investor confidence ahead of Phase 3, potentially lifting the stock.
Earnings beat may support modest upside but guidance unchanged limits upside potential.
Positive Phase 2 results de‑risk alixorexton and could lift Alkermes' valuation ahead of Phase 3.
Positive efficacy and safety data may boost investor confidence and drive near-term price appreciation.
alphai scores every news story that mentions ALKS with an AI model for sentiment and relevance, and aggregates insider trades from Alkermes plc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Alkermes (ALKS) officer Craig C. Hopkinson filed a Rule 144 notice for potential sales of 9,000 ordinary shares, valued at $422,874.27. The shares include those from an employee stock option exercise, performance share award vesting, and restricted stock unit vesting. Alkermes had 167,763,272 ordinary shares outstanding as of 09/01/2026.
1 min readAlkermes' investigational narcolepsy drug alixorexton showed statistically significant improvements in wakefulness and cataplexy in a phase 2 study. The treatment was well-tolerated and improved patient-reported outcomes. The company has initiated a phase 3 program based on these results, according to the company.
2 min readAlkermes (ALKS) shares rose 1.7% since its last earnings report, beating estimates with Q2 2026 revenue of $496M (up 27% YoY) and break-even earnings. Key products like Vivitrol and Lybalvi showed mixed sales growth. The company reiterated its 2026 guidance, expecting $1.73B-$1.84B in total revenue. Analysts have revised estimates downward, and the stock has a Zacks Rank #3 (Hold).
2 min readAlkermes (ALKS) reported positive Phase 2 data for alixorexton in narcolepsy, leading to a global Phase 3 trial launch. The data, published in The Lancet Neurology, showed significant improvements in wakefulness and safety. The company aims for $2.3B revenue by 2029, with analysts projecting up to $2.8B. Success hinges on Phase 3 trial outcomes.
2 min readAlkermes (ALKS) announced positive phase 2 study results for alixorexton in adults with narcolepsy type 1, published in The Lancet Neurology. The study showed statistically significant improvements in wakefulness and cataplexy, with all doses well-tolerated. Alkermes has initiated phase 3 trials for alixorexton in narcolepsy types 1 and 2.
2 min readThe FDA approved oveporexton (Orzeyful), the first drug aimed at the root cause of type 1 narcolepsy, according to the FDA and Takeda. Takeda’s phase III trials enrolled 273 patients and reported improved daytime wakefulness and nighttime sleep, plus symptom improvements including cataplexy, sleep paralysis, and hallucinations. Alkermes is also developing a narcolepsy treatment.
6 min readAlkermes plc (ALKS) amended its senior secured term loan credit agreement to reduce borrowing costs on $1.52 billion of term loans. According to the company, Amendment No. 1 lowers the TLA spread by 75 bps and the TLB spread by 50 bps. TLA ($745.3m) and TLB ($773.1m) mature in 2031.
1 min readAlkermes plc. (ALKS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Term Loan Credit Facilities On August 12, 2026, Alkermes plc (the “Company”) entered into Amendment No. 1 to Credit Agreement (the “Amendment”), which amends the Credit Agreement, dated as of February 12, 2026 (the “Credit Agr
3 min readAlkermes plc (NASDAQ:ALKS) fell about 5% to $50.05 after its Q2 2026 report. Revenue rose 27% year over year to $496.0 million, driven by proprietary net sales of $411.7 million and LUMRYZ net sales of $96.6 million. GAAP net income dropped to $0.5 million from $87.1 million, while adjusted EBITDA rose to $139.2 million. The company also announced a CEO transition from Richard Pops to Blair Jackson on Aug. 1.
5 min readAlkermes (ALKS) reported Q2 2026 revenue of $496.01M and net income of $0.50M, with guidance for Q3 2026 revenue of $450M to $470M. The company expects a full-year 2026 GAAP net loss of $95M to $115M. Alkermes paused buybacks after repurchasing 5.32% since 2024 and filed a $311.11M employee share plan shelf.
4 min read
